Novo Nordisk invests DKK 800 million in upgrading and expanding production facilities in Kalundborg
Bagsværd, Denmark, 7 February 2020 – Novo Nordisk today announced plans to invest DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg, Denmark.
The facilities currently manufacture a range of products for diabetes treatment and will be rebuilt and expanded to allow for future production of these products as well as the next generation of diabetes products. The projects are expected to be completed in 2022.
“This investment in our production facilities highlights our ambition to continue strengthening our presence in Denmark and Kalundborg. Today, we manufacture around half of the world’s insulin in Kalundborg where we have been present for 50 years. Since the turn of the millennium alone, we have invested more than DKK 16 billion in these facilities, which are a cornerstone of our global production network”, said Michael Hallgren, senior vice president for Novo Nordisk production in Kalundborg.
About Novo Nordisk Kalundborg
Established in 1969, the site covers a total area of 1,200,000 square metres and employs more than 3,000 people. Besides diabetes products a range of biopharmaceutical products are also produced at the production site in Kalundborg.